rs183894680
Positions:
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The ENST00000265709.14(ANK1):c.127-39554G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0182 in 1,200,424 control chromosomes in the GnomAD database, including 209 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.016 ( 28 hom., cov: 32)
Exomes 𝑓: 0.018 ( 181 hom. )
Consequence
ANK1
ENST00000265709.14 intron
ENST00000265709.14 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.289
Genes affected
ANK1 (HGNC:492): (ankyrin 1) Ankyrins are a family of proteins that link the integral membrane proteins to the underlying spectrin-actin cytoskeleton and play key roles in activities such as cell motility, activation, proliferation, contact and the maintenance of specialized membrane domains. Multiple isoforms of ankyrin with different affinities for various target proteins are expressed in a tissue-specific, developmentally regulated manner. Most ankyrins are typically composed of three structural domains: an amino-terminal domain containing multiple ankyrin repeats; a central region with a highly conserved spectrin binding domain; and a carboxy-terminal regulatory domain which is the least conserved and subject to variation. Ankyrin 1, the prototype of this family, was first discovered in the erythrocytes, but since has also been found in brain and muscles. Mutations in erythrocytic ankyrin 1 have been associated in approximately half of all patients with hereditary spherocytosis. Complex patterns of alternative splicing in the regulatory domain, giving rise to different isoforms of ankyrin 1 have been described. Truncated muscle-specific isoforms of ankyrin 1 resulting from usage of an alternate promoter have also been identified. [provided by RefSeq, Dec 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -13 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.8).
BP6
Variant 8-41797691-C-T is Benign according to our data. Variant chr8-41797691-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 512.We mark this variant Likely_benign, oryginal submissions are: {Benign=1, Uncertain_significance=1}.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.016 (2438/152206) while in subpopulation NFE AF= 0.0182 (1238/67994). AF 95% confidence interval is 0.0174. There are 28 homozygotes in gnomad4. There are 1139 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 28 AD,AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ANK1 | NM_001142446.2 | c.127-39554G>A | intron_variant | NP_001135918.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ANK1 | ENST00000265709.14 | c.127-39554G>A | intron_variant | 1 | ENSP00000265709 | P4 | ||||
ANK1 | ENST00000705521.1 | c.127-39554G>A | intron_variant | ENSP00000516136 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0160 AC: 2426AN: 152090Hom.: 27 Cov.: 32
GnomAD3 genomes
AF:
AC:
2426
AN:
152090
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0185 AC: 19358AN: 1048218Hom.: 181 AF XY: 0.0180 AC XY: 9183AN XY: 511456
GnomAD4 exome
AF:
AC:
19358
AN:
1048218
Hom.:
AF XY:
AC XY:
9183
AN XY:
511456
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0160 AC: 2438AN: 152206Hom.: 28 Cov.: 32 AF XY: 0.0153 AC XY: 1139AN XY: 74398
GnomAD4 genome
AF:
AC:
2438
AN:
152206
Hom.:
Cov.:
32
AF XY:
AC XY:
1139
AN XY:
74398
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
7
AN:
3478
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:1Benign:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Spherocytosis, type 1, autosomal recessive Pathogenic:1Benign:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2000 | - - |
Benign, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NG_012820.1(NM_001142446.2):c.127-39554G>A in the ANK1 gene has an allele frequency of 0.02 in African subpopulation in the gnomAD database. 6 homozygous occurrences are observed in the gnomAD database. This variant was reported as -153G-A in a hereditary spherocytosis patient (PMID: 11102985). Benign computational verdict because benign prediction from DANN. Taken together, we interprete this variant as Benign/Likely benign variant. ACMG/AMP criteria applied: BS1, BS2, BP4. - |
not provided Uncertain:1Benign:1
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2024 | ANK1: BS1, BS2 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | May 19, 2023 | BS1, BS2, BP4, BP7 - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at